Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

Home Blog Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

Thank You!

Click below to view the webinar recording.

Do you have a gene or cell therapy program needing expert bioanalytical support?

Let’s talk scientist-to-scientist about how we can help.

BioAgilytix’s team is committed to helping sponsors pursue the opportunities in these compelling therapeutic modalities with expert guidance on the bioanalytical aspects of their clinical development. If you have a program you’d like to discuss, set a time to speak with our scientists below!

Did You Know?

Did You Know Image 0

BioAgilytix has supported more than 20 in vivo gene therapy programs since 2014

Did You Know Image 1

We have also supported assessments for more than 60% of the FDA-approved cell therapies on the market today

Did You Know Image 2

Our team supported 40% of the biologics approved by the FDA from 2018-2019